Clinical Trial Update: A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

View source ↗

Summary

A completed clinical trial in India studied Tafamidis for transthyretin amyloid cardiomyopathy. The study was sponsored by Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Tafamidis (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin Amyloid Cardiomyopathy | Status: COMPLETED